4 Results for "

GC-IN-2

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "GC-IN-2" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-13963
CAS No.: 587841-73-4
Purity:  98.49%
ZCL278 is a selective Cdc42 inhibitor with Kds of 6.4 μM in fluorescence titration and 11.4 μM in surface plasmon resonance (SPR) measurement. ZCL278 is able to disrupt the Cdc42-ITSN interaction as well as GTP/GDP binding. ZCL278 has inhibitory effects on various enveloped viruses, but is ineffective against non-enveloped viruses. ZCL278 can be used for the studies of arsenic neurotoxicity and HER2-positive gastric cancer (GC) .
loading...
    loading...
Cat. No.: HY-165420
CAS No.: 333441-43-3
Target:  

Glycosidase

Research Areas:  

Others

GC-IN-2 (Compound 25) is a potent, selective, and nonsugar glucocerebrosidase inhibitor with an IC50 of 6.46 μM. GC-IN-2 can be utilized in research related to Gaucher disease .
loading...
    loading...
Cat. No.: HY-156020
CAS No.: 851185-20-1
Target:  

Glycosidase

Research Areas:  

Metabolic Disease

Glucocerebrosidase-IN-2 (compound 12) is a quinazoline analogue and an inhibitor of glucocerebrosidase (GC). Glucocerebrosidase-IN-2 has the potential to improve GC translocation to lysosomes in Gaucher disease patient-derived cells (mostly carrying the N370S mutation). Glucocerebrosidase-IN-2 inhibits the hydrolysis of 4-methylumbelliferone β-D-glucopyranoside (4MU) and fluorescent glycosylceramide (FlourGC) in N370S mutant tissues with an AC50 of 25.29 μM .
loading...
    loading...
Cat. No.: HY-13963S
ZCL278- 13C is a 13C-labeled version of ZCL278 (HY-13963). ZCL278 is a selective Cdc42 inhibitor with Kds of 6.4 μM in fluorescence titration and 11.4 μM in surface plasmon resonance (SPR) measurement. ZCL278 can disrupt the interaction between Cdc42 and ITSN, and also inhibit the binding of GTP and GDP. ZCL278 has inhibitory effects on various enveloped viruses, but is ineffective against non-enveloped viruses. ZCL278 can be used in the research of arsenic neurotoxicity and HER2-positive gastric cancer (GC) [1][2][3][4].
loading...
    loading...